N= 29,157,460	%

Sex

 Male	49.9

 Female	50.1

Age

 6 to 11	7.4

 12 to 19	11.4

 20 to 39	30.9

 40 to 59	33.5

 60 to 79	16.8

Smoking Status

 Never smoked	52.6

 Past smoker	27.1

 Current smoker	20.3

Education

 Degree/diploma	49.6

 <Degree/diploma	50.5

Immigrant Status

 Born in Canada	79.0

 Not born in Canada	21.0

Aboriginal Status

 Non-Aboriginal	96.9

 Aboriginal	3.10

Income adequacy

 Highest income	47.9

 Middle income	31.9

 Lowest income	20.3

Dental insurance

 Private coverage	62.3

 Public coverage	5.8

 Non-insured	31.9

Self-reported oral health

 Excellent/very good/good	84.5

 Fair/poor	15.5

Self-reported general health

 Excellent/very good/good	91.9

 Fair/poor	8.1

Self-reported oral pain

 Rarely/never	88.4

 Often/sometimes	11.6

Self-perceived unmet needs

 No needs	67.0

 Has at least one need	33.0

Brushing frequency

 >Once/day	72.0

 Once/day	24.6

 <Once/day or Never	3.4

Flossing Frequency

 >Once/day	8.6

 Once/day	21.4

 <Once/day	42.0

 Never	28.1

Avoided dental treatment due to cost

 No	83.5

 Yes	16.5

Last Dental Visit

 In the last year	74.5

 More than one year ago	25.5

Dental Visit Frequency

 > Once a year	42.6

 Once a year	31.7

 < Once a year	9.2

 Only for emergency	13.3

 Never	3.2

Work/School Days Lost

 No	60.9

 Yes	39.2


Target mRNA	Sequence(5’-3’)	Product size

(Accession number)	 	(bp)

hOCT1/SLC22A1	AATGGACCACATCGCTCAAAA

(NM_003057)	CTTCGAGGGAAAGCATCTTTAAAT	68

hOCT2/SLC22A2	GGACGGCTGGGTGTACGA

(NM_003058)	GGAGTTGGCACATACCAGGTTAA	70

hOCT3/SLC22A3	CATGCCTTGTCACTGCGTTCT

(NM_021977)	ATGTAGCCACTGTGGTCCTCAA	63

hOCTN1/SLC22A4	CCAGAGTGGGCAGCATCAT

(NM_003059)	TAGGGCAGCATTCTGTTGTAAGC	67

hOCTN2/SLC22A5	CCTTCTCTTCATGCAGCTGGTA

(NM_003060)	CCCACCATCACCAGGACTGT	66

hMATE1/SLC44A1	CAGTCACGCTGGCAATCG

(NM_080546)	GGTGTCACAGGCAGAAGATAAGC	77

hMATE2/SLC44A2	TCTGAGAGGAACTGGGAAGCA

(NM_152908)	AGGCCGATGATGTAATATGTGATG	69

hPMAT/SLC29A4	CAGCTTTCACGGATACTACATTGG

(NM_001040661)	GCAAAGTAGATGGCGTGATAACG	67

hGAPDH	CCACATCGCTCAGACACCAT

(NM_002046)	GCGCCCAATACGACCAAAT	66


Item	People with diabetes are advised to regularly check their feet and the inside of their shoes. People differ a lot with respect to the importance they attach to “good advice“ of this kind. How important is this advice for you personally?

Reply options	not important	a little important	important or very important

Tailored answer	OK, so this recommendation is not important for you. Maybe you are very aware of the inconvenience of daily foot care. You are right there; it takes some effort in the beginning. At the same time it helps a lot to prevent diabetic foot syndrome. A diabetic foot can be painful and can lead to amputation. There is a great benefit for the comparatively small effort of taking care of your feet. For many people the first step is the hardest. Once you get used to it, the effort does not seem so great anymore.	OK, so this recommendation is a little important for you. Maybe you are aware of the inconvenience of daily foot care. At the same time it helps a lot to prevent diabetic foot syndrome. A diabetic foot can be painful and can lead to amputation. There is a great benefit for the comparatively small effort of taking care of your feet. For many people the first step is the hardest. Once you get used to it, the effort does not seem so great anymore.	You are right, this recommendation is really important. Looking after your feet can be inconvenient but helps a lot to prevent diabetic foot syndrome. A diabetic foot can be painful and can lead to amputation. There is a great benefit for the comparatively small effort of taking care of your feet.


Patient ID	Sample ID	Gender	Age at test	Type of cancer	Sample type

1	F1311260008	Female	64	Lung cancer, SCC	FFPE

2	B1312160009	Female	61	Colon cancer	Blood

3	F1312230017	Male	54	Lung cancer, SCC	FFPE

4	F1401170002	Male	57	Rectal cancer	FFPE

5	F1401170004	Male	53	Lung adenocarcinoma	FFPE

6	F1402240017	Male	20	Neuroectodermal tumor	FFPE

7	F1410200833B1410200832	Female	52	Lung adenocarcinoma	FFPE

8	C1409280774B1409280773	Male	67	Lung adenocarcinoma	Pleural fluid

9	F1411100940B1411100938	Female	53	Breast cancer	FFPE

10	F1412241251B1412241250	Female	66	Lung adenocarcinoma	FFPE


Variable†		Odds ratio	95% CI‡

Pretreatment HCV RNA level§	Per 1 log increase	0.179	0.096–0.336

HCV genotype	1b = 1; non-1b = 0	0.324	0.151–0.695

IFN-α regimen	6-MU = 1; 3-MU = 0¶	2.310	1.070–4.990

Stage of fibrosis	F3–4 = 1; F0–2 = 0	0.408	0.104–0.892


Family	Millet Zhang gu	Millet Yugu1	Maize

AUX/IAA	29	29	52

GIF	3	3	3

MBF1	2	2	3

Med10	1	1	2

Med11	1	1	2

Med12	1	1	6

Med13_C	1	1	1

Med14	2	2	1

Med17	1	1	2

Med18	1	1	0

Med20	1	1	1

Med22	1	1	1

Med31	1	1	1

Med4	1	1	2

Med6	1	1	2

Med7	2	2	2

PC4	2	2	3

RB	2	2	5

Sigma54_activat	9	10	9

Spt20	2	2	1

TAZ	7	7	7

OFP	33	27	43


Variables	Frequency	Percentage

Age	15-19 years	16	3.8

20-34 years	333	79.5

35-49 years	70	16.7

Mean ±SD	 	(27.4 ± 6.1)

Literacy status	No schooling	134	32

Schooling	285	68

Occupation	House wife	240	57.3

Other*	179	42.7

Average monthly family income	below 401	134	31.7

401-1000	174	41.8

above 1000	111	26.5

Mean ±SD	 	(797.3 ±669.9)

Family size	1-3	123	29.4

4-5	203	48.4

above 5	93	22.2

Mean ±SD	 	(4.6±1.7)

Media exposure	No exposure	122	29.1

Radio or TV	150	35.8

 	Radio and TV	147	35.1


	Forensic autopsy

Molecular autopsy	+ (n = 26)	− (n = 24)

+ (n = 14)	9	5

− (n = 36)	17	19


Assembly names	A	B	C	D

Assembly tools

Contig assembly tool	Fermi	Fermi	SOAPdenovo2	SOAPdenovo2

Scaffolding tool	SOAPdenovo2	SSPACE	SOAPdenovo2	SSPACE

Gap closing tool	GapCloser	GapCloser	GapCloser	GapCloser

Assembly metrics

Total contigs (>1,000 bp)	71,429	71,429	189,566	189,566

 Contig N50	54,944	54,944	4,048	4,048

 Contig CEGMA (%)*	96.37(77.42)	96.37(77.42)	68.15(33.06)	68.15(33.06)

 Contig BUSCO (%)	86(65)	86(65)	42(21)	42(21)

Total scaffolds (>1,000 bp)	14,417	40,372	20,466	-

 Final N50	555,585	110,915	331,639	-

 Final CEGMA (%)	95.56(81.85)	95.97(88.71)	95.97(90.73)	-

 Final BUSCO (%)	91(74)	86(64)	94(80)	-

Quality

 Percentage of Ns (%)	0.06322	0.0135	0.02622	-

 REAPR error-free bases (%)	96.46	95.35	94.98	-

 REAPR low-scoring regions	18	16	71	-

 REAPR incorrectly oriented reads	11,543	5,329	28,964	-


Project	Primer sequences	Amplified fragment length

GAPDH	F: 5′ GAAGAGTGGGTGTCGCTGTT 3′	141 bp

R: 5′ CTGCCGTCTGGAAAAACCT 3′

CREB	F: 5′ GTGCCAGCCTTTCCTTACAC 3′	109 bp

R: 5′ CACAAACCCACTGATGAACG 3′


Groups	Number of clusters	Number of clones	Clones/clusters	% of total	Putative identification

1	542	741	1.37	24.6	No Hit*

2	91	489	5.37	16.3	Sphingomyelinase D*

3	59	248	4.20	8.2	Metalloproteinase*

4	83	105	1.27	3.5	Unknown Function*

5	9	75	8.33	2.5	Troponin

6	4	55	13.75	1.8	Actin

7	14	46	3.29	1.5	Hsp*

8	7	43	6.14	1.4	Elongation Factor

9	7	41	5.86	1.4	Salivary protein*

10	3	38	12.67	1.3	5'-nucleotidase*

11	7	36	5.14	1.2	Myosin

12	5	26	5.20	0.9	Chitinase*

13	4	23	5.75	0.8	Tubulin

14	2	23	11.50	0.8	LIM protein

15	6	22	3.67	0.7	PDI*

16	2	18	9.00	0.6	Venom allergen III*

17	6	15	2.50	0.5	Lectin*

18	12	14	1.17	0.5	Serine Protease*

19	2	13	6.50	0.4	ATP-binding

20	9	12	1.33	0.4	Ubiquitin


rA - ra	Number of generations needed for the relative proportion of a clone to change from 1% to 99%

0.01	919

0.05	184

0.10	92

0.50	18

0.75	12

1.00	9

2.00	5

5.00	2


Sample type	Origin	Origin	Period/yearsbefore present	Numberof samples	Reference	PUBMED ID	SRA accession

Completeground teeth	Published works	England	750–650	6	Adler et al.9	23416520	ERP002107

		Germany	1000–400

			7400–6725

			4150–3600

		Germany	800–1100	14	Warinner et al.8	24562188	SRP029257

Dental root canal		Brazil	Modern	17	Santos et al.10	22132218	ERP000669

Dental pulp	This study	France	First World War (WWI)	6	N/A	N/A	SRP068830

		Nigeria	500	15

		France	Modern	2

Dental calculus	Published works	England	750–650	55	Adler et al.9	23416520	ERP002107

		Germany	1000–400

			1100–850 4100–2800

			4150–3600 4450–4000

			7400–6725 7550–5450

		Germany	800–1100	4	Warinner et al.8	24562188	SRP029257

Saliva		US	Modern	29	Pride et al.11	22158393	SRA024393

		US	Modern	9	The HMP (Gevers et al.)12	22904687	SRP002395

Oral cavity (diverse regions)		US	Modern	68	The HMP (Gevers et al.)12	22904687	SRP002395

Soil		Germany	Modern	18	Will et al.13	20729324	SRA020168

		Different environments	Modern	151	Bates et al.14	21085198	N/A


Disease	Cell surface DAF deficiency	Citation

Immune dysregulation

 Sjogren's Syndrome	T-lymphocytes	[36]

 SLE with lymphopenia and anemia	T-lymphocytes (CD8+), endothelium, lymphocytes, and anemia	[38, 41, 73]

 Psoriatic skin	Epithelium and endothelium	[39]

 Systemic sclerosis	Endothelium	[37]

 Vasculitic skin lesions	Endothelium	[35]

 Recurrent pregnancy loss in aPL	Endometrium	[42]

 Autoimmune hemocytopenia	Platelets, lymphocytes, and RBC	[43, 44]

 Rheumatoid arthritis	Neutrophils and RBC	[45, 46]

 Myasthenia gravis	SNP with decreased expression	[47]

 Vitiligo	Whole epidermis	[48]

 Asthma	Bronchial epithelial cells and SNP	[49, 50]

Proliferative disorders

 Myelodysplastic syndrome	Granulocytes and RBC	[51, 52]

 Plasma cell dyscrasias	RBC	[53]

 Lymphoproliferative disorders	RBC	[54]

Anemias

 Anemia of malaria	RBC	[55–59]

 Aplastic anemia	RBC	[51]

 HIV	RBC, lymphocytes, and PBMC	[60, 61]


Authors	Study subjects	Substances	Insults	Results

Broekhuizen [67]	Patients	Sulodexide	Diabetes mellitus type 2	GCX thickness increased

Gao [71]	Rats	Hydrocortisone	Pancreatitis	Improved intestinal perfusionAttenuation of Syn-1 and HA release

Nordling [72]	Endothelial cells	Immobilized heparin conjugate	IRI	Attenuation of thrombotic disorder

Strunden [75]	Isolated mouse lung	HES	Heparinase	HES attenuated interstitial edema, increased pulmonary arterial pressure

Chappell [70]	Isolated guinea pig heart	Corticosteroid	IRI	Increase in Syn-1 and reduction in HS

Chappell [79]	Isolated guinea pig heart	Sevoflurane	IRI	Increase in Syn-1 and reduction in HS


Area	Example	Potential utility	Limitations

Risk prediction	Predict new-onset AF or AF-related morbidity (stroke, heart failure, mortality risk)	Benchmark for clinical trial development	Absence of known preventive strategies for AF

		Facilitate AF and clinical outcome prevention	Cohorts for genetic risk score derivation predominantly of European ancestry

			Small relative risks of discovered variants

			Complexity of incorporation into clinical practice

			Cost

			Untested

	Predict AF progression	Early antiarrhythmic or ablation intervention	Unclear relations between AF progression and morbidity and mortality

			Untested

Patient management	Pharmacogenetics	Maximize efficacy, minimize adverse effects	Development of novel agents with wide therapeutic margins

		Thromboembolism prophylaxis	Ablation and mechanical interventions as alternatives

		Antiarrhythmic therapy	Complexity of incorporation into clinical practice

			Cost

			Untested


Group	Number of Subjects	Average Age (Range)	Average Height, cm	Average Mass kg	Average Vital Capacity, L

Females	29	25.5 ± 3.7 (18 to 31)	164 ± 6	60.5 ± 13.3	3.58 ± 0.63

Males	19	26.5 ± 4.3 (19 to 34)	177 ± 7	74.1 ± 8.8	4.72 ± 8.4


History	 No abnormality on IPS	Abnormality on IPS	Total

Family history of epilepsy	16	0	16

Consanguinity	14	1	15

No family history	94	12	106

Total	124	13	137


Types of substance	Frequency 	Percent

Alcohol use (n = 489)

 Yes	42	8.6

 No	447	91.4

Period of alcohol use (n = 42)

 ≤5 years	20	47.6

 6–10 years	12	28.6

 ≥11 years	10	23.8

Cigarette smoking (n = 489)

 Yes	55	11.2

 No	434	88.8

Period of cigarette smoking (n = 55)

 ≤5 years	10	18.2

 6–10 years	24	43.6

 ≥11 years	21	38.2

Psychoactive drugs use (n = 489)

 Yes	96	19.6

 No	393	80.4

Type of psychoactive drugs used (n = 96)

 Shisha	7	7.3

 Khat	89	92.7


Food group	Items awarded 1 point	ARFS

Vegetables	>4 vegetables per day; potatoes cooked without fat; tomatoes fresh/canned; lettuce/endive/salad greens; carrots; cabbage/brussels sprouts; cauliflower; broccoli; celery; silver beet or spinach; peas; green beans; bean sprout or alfalfa sprout; pumpkin; onion or leeks; sweet corn; sweet potato; coleslaw; mushrooms; zucchini	20

Fruits	2 pieces of fruit/day; 1/week of each of fruit or vegetable juice; canned or frozen fruit; oranges or other citrus; apples; pears; bananas; melons (water, rock, honeydew); pineapple; strawberries; apricots; peach/nectarines; mango/pawpaw; avocado	14

Protein foods	Nuts; peanut butter or peanut paste; 1–4/week of each of beef, lamb, pork, chicken, fish (steamed, baked, or grilled fish/canned (salmon, tuna, sardines)); ≥1/week of each of baked beans, soya beans/soy beans and tofu; use up to 2 eggs per week	11

Grains	≥1/week of each of the following bread types with high fibre, wholemeal; ≥4 slices bread per day; ≥1/week All-Bran, Sultana bran, FibrePlus, Branflakes, Weetbix, VitaBrits, Weeties; rice; pasta/noodles	12

Dairy	Reduced fat or skim; 500 mL/day; cheese 1/week; ice-cream; yoghurt 1/week; use ricotta/cottage cheese; use low-fat cheese	7

Fats	Use nil/polyunsaturated/monounsaturated margarine	1

Alcohol	Drink beer/wine/spirits 1/month up to 4 days/week; or 2 glasses maximum/day	2


	Sex	Age	Pressure (mmHg)	Echo Vol (ml)	Echo EF (%)	Patient MI and catheter information

Min	Max	Min	Max

Infarct Group

 P1	M	60	10	121	103	176	41.48	Inferior and posterior MI, 90 % stenosis LAD; 80 % stenosis LCX, 100 % stenosis mid MCA

 P2	F	72	8	96	50	98	48.98	Anterior myocardial infarction, 30 % stenosis proximal LAD,100 % in the proximal-mid LAD, LCX, RCA

 P3	M	73	9	105	115	193	40.41	Inferior and posterior MI, 90 % stenosis proximal and distal LAD; 90 % stenosis proximal LCX, 99 % stenosis in mid LCX, 50 % stenosis in the mid RCA, total occlusion of distal RCA

 P4	M	71	10	120	134	228	41.23	Anterior myocardial infarction, apical left ventricular aneurysm;), 100 % stenosis proximal LAD, 40 % stenosis proximal-mid LCX, 40 % stenosis in the mid RCA

 P5	M	58	9	110	70	147	52.38	anterior myocardial infarction, 40 % stenosis in LM, total occlusion of proximal LAD, 80 % stenosis mid LCX, 40 % stenosis mid RCA, total occlusion distal RCA

 Mean ± SD	66.8 ± 7.19	9.2 ± 0.84	110.4 ± 10.5	94.4 ± 34.0	168.4 ± 49.1	44.9 ± 5.4

Non-Infarcted Group

 P6	M	48	9	115	46	116	60.34

 P7	F	43	10	130	46	120	61.67

 P8	M	59	10	118	33	79	58.23

 P9	M	43	9	115	51	120	57.5

 P10	M	56	10	138	46	121	61.98

 Mean ± SD	49.8 ± 7.40	9.6 ± 0.55	123.2 ± 10.3	44.4 ± 6.7	111.2 ± 18.1	59.9 ± 0.02

 P value*	0.06	0.40	0.09	0.01	0.04	0.0004


Group	DEG	Fold change (log2,

		vs. Model)

Martynoside	Rny1 (RNA, Y1 small cytoplasmic, Ro-associated)	-7.74

	Hist1h4a (histone cluster 1, H4a)	-1.85

	Opn3 (RNA, Y1 small cytoplasmic, Ro-associated)	1.29

	Supt4b (suppressor of Ty 4B)	-1.21

	Tnnt3 (troponin T3, skeletal, fast)	-1.15

R2	Egr4 (early growth response 4)	-6.85

	Cdkn1a [cyclin-dependent kinase inhibitor 1A (P21)]	-3.33

	Ets2 (E26 avian leukemia oncogene 2, 3′ domain)	-3.18

	Sap25 (sin3 associated polypeptide)	2.98

	Il4i1 (interleukin 4 induced 1)	2.93

Rg2	Tnnc2 (troponin C2, fast)	2.75

	Amigo2 (adhesion molecule with Ig like domain 2)	2.07

	Col8a1 (collagen, type VIII, alpha 1)	-1.95

	Map7 (microtubule-associated protein 7)	1.92

	Car3 (carbonic anhydrase 3)	-1.70


Radiologic Impression/Technique	Patient	BI-RADS Category	Needle Gauge (G)	Pieces of tissue in specimen	Pieces of tissue imaged	Pathologic diagnosis

Calcium positive/mammogram	1	4	11	7	1	Fibrocystic changes with calcifications

mass/mammogram, ultrasound	2	4	14	4	1	Fibrocystic changes with calcifications

mass/sonogram	3	3	14	3	1	Fibrocystic changes with apocrine metaplasia

Calcium positive/mammogram	4	4	11	5	1	Ductal carcinoma in situ

Speculated mass/Mammogram, sonogram	5	4	14	3	1	Infiltrating ductal carcinoma

Mass/mammogram, ultrasound	6	5	14	2	1	Infiltrating lobular carcinoma

Palpable mass/ultrasound	7	5	14	5	1	Poorly differentiated infiltrating ductal carcinoma


Studies	Patients	Inter- ventions	Relevant outcomes	Size of effect	Benefits and harms	Factors influencing the clinical relevance

Barker et al. (2008) [15]	YES	NO	NO	NO	YES	Patients: Pre-treatment surgery is poorly described. Intervention is poorly described. Results 6 weeks and 12 weeks post-treatment are not integrated.

Hohmann et al. (2012) [20]	NO	NO	YES	NO	YES	Patients: Pregnancy is poorly described, although 15 patients out of 21 were women. Intervention is poorly described.

Morone et al. (2011) [16]	YES	YES	YES	YES	YES	Patients: Pre-treatment surgery is poorly described.

Paolucci et al. (2012) [37]	YES	YES	NO	NO	YES	Patients: Pre-treatment surgery is poorly described. Function is no outcome measure.

Ryan et al. (2014) [38]	NO	YES	YES	NO	YES	Patients: Pre-treatment surgery or pregnancies are poorly described. Ratio men / women is not documented.

Vetrano et al. (2013) [39]	YES	YES	YES	YES	YES	There have been remarkably more women included in this study than men. Intervention 2 (Control group) received also a SFT.


	IORT	APBI	EBRT

	%Vol > 0.1 Gy	%Vol > 4 Gy	%Vol > 0.1 Gy	%Vol > 4 Gy	%Vol > 0.1 Gy	%Vol > 4 Gy

Ipsilateral Breast	84.5	18.1	88.2	54.4	99.9	99.9

Contralateral breast	< 1	0	< 1	0	97.7	1.3

Ipsilateral Lung	4.5	0	5.0	1.3	98.8	10.1

Contralateral lung	< 1	0	< 1	0	87	0

Heart	1.8	0	4.2	0	98	0

Spine	< 1	0	< 1	0	92	0


Sections	Multidisciplinary expertise	Hardware	Software

2.1: Fluorescent protein behavior	Molecular biology, biochemistry	n.a.	n.a.

2.2–2.4: Microscopy	Cell biology, biophysics, optics	Microscope control system	Time series, stage control, autofocus

2.5: Cell physiology	Cell biology	Incubation control system	n.a.

2.6: Image analysis	Math/physics	High performance computer	Image segmentation, tracking

2.7: Population sampling	Statistics	High performance computer	Statistical analysis

2.8: Network modeling	Math/physics/engineering	High performance computer	Mathematical modeling


Site	Number	Morphology	Number	Comorbid diseases	Number

Local recurrence alone	4 (12.9%)	Adenocarcinoma	4 (12.9%)	Hypertension Diabetes	2 (6.4%) 2 (6.4%)

Pelvic lymph node	3 (9.6%)	Adenocarcinoma	3 (9.6%)	Diabetes COPD	2 (6.4%) 1 (3.2%)

Persistent	2 (6.4%)	Adenocarcinoma Clear cell carcinoma	1 (3.2%) 1 (3.2%)	Diabetes	2 (6.4%)

Distant	5 (16.1%)

Lung	2 (6.4%)	Adenocarcinoma	2 (6.4%)	Hypertension Diabetes	1 (3.2%) 1 (3.2%)

Multi-organ	2 (6.4%)	Adenocarcinoma	2 (6.4%)	Hypertension SLE	1 (3.2%) 1 (3.2%)

Bone	1 (3.2%)	Adenocarcinoma	1 (3.2%)	Diabetes	1 (3.2%)


Patient	Target lesion	SUVmax prea	SUVmax postb	ΔSUVmaxc (%)	RECISTd

1	Mediastinal mass	10.00	7.50	−25	PR

2	Mediastinal mass	6.60	3.50	−47	PR

3	Mediastinal mass	13.00	6.20	−52	SD

4	Pleural implant	9.23	0.00	−100	CR

5	Mediastinal mass	4.10	3.00	−27	PR

6	Lung lesion	18.70	17.00	−9	SD

7	Lymph node	12.00	11.50	−4	SD

8	Pleural implant	5.80	2.10	−64	PR

9	Pleural implant	7.60	1.70	−78	PR

10	Lymph node	3.70	8.20	120	PD

11	Mediastinal mass	4.19	5.30	26	SD

12	Mediastinal mass	8.40	11.30	35	SD

13	Lung lesion	19.70	5.70	−71	PR

14	Mediastinal mass	4.20	4.60	10	PR

15	Mediastinal mass	5.00	3.00	−40	PR

16	Mediastinal mass	8.40	0.00	−100	CR

17	Pleural implant	4.00	4.80	20	PD

18	Mediastinal mass	15.60	18.5	19	PR

19	Mediastinal mass	7.70	2.20	−71	PR

20	Lung lesion	8.80	14.40	64	SD

21	Mediastinal mass	8.30	5.70	−31	PR

22	Lymph node	8.50	5.40	−36	PR

23	Pleural implant	3.30	1.90	−42	PR

24	Mediastinal mass	7.00	4.50	−36	SD

25	Mediastinal mass	5.60	1.80	−68	PR

26	Mediastinal mass	20.00	15.00	−25	PR

27	Mediastinal mass	4.80	6.70	40	SD


No.	Location	RT-PCR	Single RT-qPCR	Duplex RT-qPCR

 	 	ACLSV	CGRMV	ACLSV	CGRMV	ACLSV	CGRMV

1	Qingdao	 	+	 	+	 	+

2	Qingdao

3	Qingdao	 	 	+	 	+

4	Qingdao

5	Qingdao

6	Qingdao	+	+	+	+	+	+

7	Qingdao

8	Qingdao	 	 	 	+	 	+

9	Qingdao

10	Qingdao	+	 	+	 	+

11	Qingdao

12	Qingdao	 	 	+	 	+

13	Qingdao

14	Shijiazhuang	+	 	+	 	+

15	Shijiazhuang

16	Shijiazhuang	+	 	+	 	+

17	Shijiazhuang

18	Shijiazhuang	 	+	 	+	 	+

19	Shijiazhuang

20	Shijiazhuang

21	Shijiazhuang

22	Shijiazhuang

23	Taian	+	 	+	 	+

24	Taian

25	Taian

26	Taian

27	Taian

28	Taian	+	+	+	+	+	+

29	Taian

30	Taian	+	 	+	 	+

31	Taian

32	Taian

33	Taian

34	Taian	+	+	+	+	+	+

Total	 	8	5	10	6	10	6


Region	County	Number of sites	Number of patients enrolled

Global (total)	 	114	1931

WEC (total)	 	74	760

 	Austria	3	18

 	Canada	6	72

 	France	8	82

 	Germany	4	70

 	Greece	4	40

 	Ireland	1	20

 	Israel	3	37

 	Italy	6	99

 	Netherlands	1	25

 	Norway	3	21

 	Portugal	6	93

 	Spain	16	87

 	Sweden	4	25

 	Switzerland	2	27

 	UK	7	44

CEE (total)	 	20	532

 	Czech Republic	3	20

 	Estonia	3	99

 	Romania	8	200

 	Russia	5	171

 	Slovenia	1	42

LA (total)	 	17	519

 	Argentina	3	101

 	Brazil	1	90

 	Chile	1	50

 	Columbia	6	84

 	Mexico	2	115

 	Venezuela	4	79

Asia (total)	 	3	120

 	China	3	120


Characteristic	Overalln=92 (%)	Culture methods 41 (%)	Molecular diagnosis 51 (%)

Treatment with first-line drug regimen (%)	92 (100)	41 (100)	51 (100)

Mean days on first-line drug (range) (n=92)	81 (14–434)	154 (73–434)	22 (14–36)

Mean days until starting MDR-TB treatment using second-line drug (range) (n=92)	44 (6–85)	73 (54–102)	5 (2–6)

Required surgery (%)	87 (95)	41 (100)	46 (90)

 Recovered without need for surgery	5	0	5


Patient	JAK2 p.V617F allele burden (%)a	MPL p.W515L allele burden (%)	Additional mutations by NGS in DNA from GR (allele burden)	HUMARA

 	RNA platelets	RNA GR	DNA GR	RNA plateletsb	RNA GRb	DNA GRc

1	20	0	1.85	2.16	0	0	ND	Clonal

2	16	10	1.8	12	33	Positive	ND	NA

3	0	 	 	26	15	Positive	ND	NA

4	0	 	 	0	 	 	MPL p.Pro222Ser (42.32%)	Clonal

5	0	 	 	0	 	 	MPL p.Ser204Pro (46.94%)	Clonal

6	0	 	 	0	 	 	TET2 p.Gln958Ter (20.17%)	Clonal

 	 	 	 	 	 	 	TET2 p.Leu1880Pro1 (15.2%)

 	 	 	 	 	 	 	CBL p.Leu380Pro (2.79%)

7	0	 	 	0	 	 	MPL p.Ser204Phe (25.69%)	Clonal

8	0	 	 	0	 	 	MPL p.Ser204Pro (37.45%)	Clonal

 	 	 	 	 	 	 	MPL p.Arg592Gln (30.56%)

 	 	 	 	 	 	 	SF3B1 p.His662Asp (3.44%)

9	0	 	 	0	 	 	TET2 p.Gln790Ter (20%)	No clonal

10	0	 	 	0	 	 	TET2 p.Ser1848Ter (44.74%)	NA

 	 	 	 	 	 	 	SH2B3 p.Trp364Ter (41.47%)

 	 	 	 	 	 	 	CBL p.Val363Gly (3.69%)

11	0	 	 	0	 	 	TET2 p.Ala1196Asp (2.41%)	NA


Patient no.	Age (years)	Diagnosis	Stage	Therapy

1	29	HD, MC	IIA	MOPP × 6, Mantle 36 Gy

2	28	HD, NS	IIB	MOPP × 4, ABVD × 4, Mantle 20 Gy

3	42	Had	IIB	ABVD × 3, Mantle 40 Gy

4	38	HD, MC	IIA	MOPP × 6, Mantle 40 Gy

5	24	HD, NS	IIB	MOPP × 6, Mantle 40 Gy

6	30	HD, NS	IIA	MOPP × 4, ABVD × 4, Mantle 36 Gy


Characteristics	N (%)

Low back pain, spine or joint disorders

No	315 (39.6)

Yes	481 (60.4)

Non-ischemic heart disease

No	433 (54.4)

Yes	363 (45.6)

Musculoskeletal disorders

No	501 (62.9)

Yes	295 (37.1)

Neurological disease

No	514 (64.6)

Yes	282 (35.4)

Hematological disease

No	606 (76.1)

Yes	190 (23.9)

Chronic respiratory disease

No	620 (77.9)

Yes	176 (22.1)

Visual impairment

No	623 (78.3)

Yes	173 (21.7)

Infections

No	644 (80.9)

Yes	152 (19.1)

Urology diseases

No	647 (81.3)

Yes	149 (18.7)

Liver, pancreas or biliary disease

No	701 (88.1)

Yes	95 (11.9)

Peripheral vascular

No	778 (97.7)

Yes	18 (2.3)


Feature	F-score	Correlation, r

ss_Abs_dSize	zsEntropy21	predRSA	varPredRSA21

Abs_dSS	0.73	0.73	−0.72	−0.38	−0.32

ss_Abs_dSize	0.61	 	−0.50	−0.28	−0.31

zsEntropy21	0.49	 	 	0.39	0.14

predRSA	0.47	 	 	 	0.42

varPredRSA21	0.45


	Case 1	Case 2

Age at onset, years/gender	65/M	50/M

Education (years)	12	16

Years of follow-up	5	7

Clinical Dementia Rating score, total (0–3) for the first 2 years	0.5	0.5

Sentence repetition	5 phrases	6 phrases

Non-word repetition	intact	intact

Forward digit span	6	6

Backward digit span	5	4

Confrontation naming in SLTA, % correct	25 (anomia)	65 (anomia)

Auditory single-word comprehension in SLTA, % correct	100	100

Auditory complex sentence commands comprehension in SLTA, % correct	20 (auditory comprehension deficits)	50 (auditory comprehension deficits)

Reading comprehension of complex sentence commands in SLTA, % correct	20 (reading comprehension deficits)	20 (reading comprehension deficits)

Written naming in Kanji in SLTA, % correct	20 (agraphia)	20 (agraphia)

Dictation of short sentences, % correct	0 (agraphia)	0 (agraphia)

Calculation in SLTA, % correct	15 (acalculia)	10 (acalculia)

Ideational apraxia	present	present

Visuoconstructional disorder	not found	present

Visuoperceptual disorder	not found	not found

Episodic memory deficits	found (2 years postonset)	Found (4 years postonset)


End point	3-Year estimate (%)	95% Confidence interval

Progression-free survival	83.0	(69.8, 98.8)

Overall survival	94.9	(89.5, 100)

Local recurrence-free survival	96.6	(92.1, 100)

Distant metastasis-free survival	89.8	(82.4, 97.9)


Osteosarcoma subtype	Osteoblastic 105 (57.1%)	Chondroblastic 40 (21.7%)	Fibroblastic 21 (11.4%)	Telangiectatic 14 (7.6%)	Others 4 (2.2%)	Total 184 (100%)

Number of “Good responders” (%)	45	19	5	6	0	75 (40.8)

Number of ‘Poor responders’ (%)	60	21	16	8	4	109 (59.2)

Number of cases with amplification (% of subtype)1	7 (6.7)	3 (7.5)	7 (33.3)	2 (14.3)	0	19


Primers	Forward	Reverse

beta-actin	GCGCGGCTACAGCTTCA	CTTAATGTCACGCACGATTTCC

PPARgamma	GCTTTTGGCATACTCTGTGATCTC	GGTGGCCATCCGCATCT

VEGF-A	GGGCAGAATCATCACGAAGT	TGGTGATGTTGGACTCCTCA

CD105	CTCTCCAGGCATCCAAGCAA	CAGGCTGGAATTGTAGGCCA

CD31	GCTGACCCTTCTGCTCTGTT	ATCTGGTGCTGAGGCTTGAC

HIF-1alpha	GCCAGACGATCATGCAGCTA	ATCCATTGATTGCCCCAGC

IL-1beta	TCAGCCAATCTTCATTGCTCAA	TGGCGAGCTCAGGTACTTCTG

Wnt5a	CAAAGCAACTCCTGGGCTTA	CCTGCTCCTGACCGTCC


Clinical features	Survivors (n = 93)	Non survivors (n = 96)	p value

Demographic factors

Mean age	59.3 ± 18.6	61.0 ±17.4	0.52

≥ 65 years age	48 (52%)	52 (54%)	0.73

Gender male/female	55/38	55/41	0.79

ATS major criteria

Use of mechanicalventilation	18 (19%)	29 (30%)	0.08

Septic shock	23 (25%)	59 (61%)	< 0.001

History

Prior antibiotic use	14 (15%)	26 (27%)	0.04

Comorbids	76 (82%)	84 (88%)	0.27

Physical examination findings

Blood pressure ≤90/60 mmHg	25 (27%)	30 (31%)	0.51

Pulse ≥ 120/min	32 (34%)	37 (39%)	0.55

Respiratory Rate30/min	56 (60%)	57 (59%)	0.95

Laboratory findings

Blood urea nitrogen ≥30 mg/dl	44 (47%)	59 (61%)	0.03

Creatinine > 1.5 mg/dL	48 (52%)	53 (55%)	0.25

Hematocrit <30%	22 (24%)	37 (39%)	0.03

Na <130 mmol/L	22 (24%)	28 (29%)	0.39

Arterial pH <7.35	28 (30%)	32 (33%)	0.63

Radiographic findings

Pleural effusion	32 (34%)	38 (40%)	0.46

Bilateral involvement	36 (39%)	53 (55%)	0.07

Multilobar involvement	28 (30%)	38 (40%)	0.22

Mean APACHE II score	19.1 ±6.0	28.2 ±7.0	<0.001

APACHE II score ≥ 20	38 (41%)	80 (83.0%)	<0.001


ICD-10-GM code	Corresponding diagnosis

I50.0	Right ventricular failure

I50.00	Primary right ventricular failure

I50.01	Secondary right ventricular failure

I50.1	Left ventricular failure

I50.11	NYHA class I

I50.12	NYHA class II

I50.13	NYHA class III

I50.14	NYHA class IV

I50.19	NYHA class not specified

I50.9	Heart failure, unspecified

I11.0	Hypertensive heart disease with (congestive) heart failure

I13.0	Hypertensive heart and renal disease with (congestive) heart failure

I13.2	Hypertensive heart and renal disease with both (congestive) heart failure and renal failure


Author	RAQ criteria for radiological bias	Association between malalignment and worse outcome	Sample size	Alignment data	Findings

Parratte et al. (2010)	Low risk	No	398	292 knees classed as mechanically aligned 0° ± 3. 10 knees in the outlier group (beyond 0° ÷ 3°	15.4 % revision rate in the mechanically aligned group. 13 % in the outlier group (p = 0.88). No association between malalignment and revision

Bonner et al. (2011)	Low risk	No	458	372 knees were classified as mechanically aligned (0° ± 3°). 86 knees were within the malaligned group	33 revisions for aseptic loosening. Kaplan–Meier survival analysis showed a weak tendency towards improved survival with restoration of a neutral mechanical axis, but this did not reach statistical significance (p = 0.47)

Magnussen et al. (2011)	Low risk	No	553	181 patients were in varus alignment, 352 were in neutral alignment and 20 were in valgus alignment	No statistically significant difference in revision rates between the three groups (p = 0.15)


		Range	Drying platform

Average	Min	Max	Rack	Black tarpaulin	Cement floor

OTA level (μg/kg)	0.569 ± 0.3	<LD	13.4	0.459 ± 0.04 a	0.665 ± 0.023 a	0.584 ± 0.026 a


Patient characteristics	Result

Patients (n)	18

Mean age (range)	62 (41–89)

Sex (n male/female)	12/6

Body mass index (kg/m2)	22.2 ± 3.7

The combined surgical risk factors:

Receiving treatment for other cancers	3

Age >85 years old and refusal of surgery	4

Hemophilia	1

Coronary heart disease	6

End-stage renal disease receiving hemodialysis	2

Dilated cardiomyopathy with heart failure	2

Mean follow-up (range), months	26.8 (12–56)

Mean tumor size (range), cm	3.3 (1.4–4.6)

Tumor location (right/left)	10/8

Pathology:

Clear cell RCC	14

Papillary RCC	3

Chromophobe RCC	1

Operative time (min)	67 ± 18

Complication

Nausea	3

Pain	4

Subcapsular hemorrhage	1

Retroperitoneal errhysis	1


Chromosome No.	Centromere Position	Relative Length (%)	Arm Ratioa	45Sb	5Sb	Satelliteb

S. oleracea L. Mazeran

 1	Submedian	19.6	1.73

 2	Submedian	18.2	2.17	S	L

 3	Subterminal	17.3	3.44

 4	Subterminal	16.0	3.36

 5	Subterminal	14.5	3.11	S	L	S

 6	Subterminal	14.4	6.61	S		S

Total length		100

S. tetrandra Stev. PI 647859

 X	Median	18.1	1.29

 Y	Median	29.9	1.12

 1	Submedian	16.7	2.39		L

 2	Submedian	16.6	2.84

 3	Submedian	14.8	1.85

 4	Submedian	17.9	1.86	S	L	S

 5	Submedian	15.9	2.46	S		S

Total length (X)		100

Total length (Y)		111.8


Gene	AT gene locus	Biological function	Act./Repr. +/-	Reference	Fragaria	E-value

Autonomous pathway

FCA	AT4G16280	RRM-type RNA binding domain containing	+	[94]	nf

FPA	AT2G43410	RRM-type RNA binding domain containing	+	[95]	nf

FLK	AT3G04610	KH-type RNA binding domain containing	+	[96]	EX668302	5E-52

FY	AT5G13480	mRNA 3' end processing factor	+	[97]	EX659635	5E-75

SKB1	AT4G31120	Arginine methyltransferase	+	[98]	nf

FVE	AT2G19520	retinoblastoma associated	+	[24]	VES-001-B03	3E-76

LD	AT4G02560	DNA/RNA binding homeodomain protein	+	[99]	DY670534	3E-49

FLD	AT3G10390	component of histone deacetylase complex	+	[23]	nf

LDL1/SWP1	AT1G62830	Histone H3-Lys 4 demetylase-like	+	[22]	Contig 2573	2E-27

LDL2	AT3G13682	Histone H3-Lys 4 demetylase-like	+	[22]	DY669828	1E-42

Gibberellin pathway

GAI	AT1G14920	putative transcriptional repressor	-	[100]	Contig 3276	3E-147

RGA	AT2G01570	putative transcriptional repressor	-	[100]	DQ195503	8E-60

SPY	AT3G11540	O-linked N-acetylglucosamine transferase	-	[101]	BAR-002-C02	2E-93

DDF1	AT1G12610	AP2-like TF	+	[102]	Contig 3158	5E-49

DDF2	AT1G63030	AP2-like TF	+	[102]	nf

AtMYB33	AT5G06100	MYB TF	+	[25]	DY669997	5E-29

FPF1	AT5G24860	Unknown	+	[103]	Contig 4074	7E-38

Other

SVP	AT2G22540	MADS-box TF	-	[57]	VES-013-D05	5E-22

AP2	AT4G36920	AP2 TF	-	[104]	VES-008-A07	9E-16

PFT1	AT1G25540	vWF-A domain protein	+	[48]	BAR-002-D08	1E-17

HRB1	AT5G49230	ZZ type zinc finger protein	+	[49]	VES-012-B01	7E-22


Variable	Description (N = 10)

Age (years old)

Mean (St. Dev.)	2.57 (0.99)

Median (min / max) 	2.21 (2; 5)

Age range, n (%)

< 3 years old	8 (80.0)

≥ 3 years old	2 (20.0)

Gender, n (%)

Feminine	4 (40.0)

Masculine	6 (60.0)

Laterality, n (%)

Unilateral	5 (50.0)

Bilateral	5 (50.0)


Variables	Frequency	Percentage

Malaria vaccine will prevent malaria

 Indifferent	40	8.0

 Agree	159	31.8

 Strongly agree	301	60.2

Everyone should receive malaria vaccine

 Disagree	15	3.0

 Indifferent	75	15.0

 Agree	103	20.6

 Strongly agree	307	61.4

I will take the malaria vaccine when produced

 Indifferent	30	6.0

 Agree	70	14.0

 Strongly agree	400	80.0

Malaria vaccine is not against our cultural belief

 Indifferent	35	7.0

 Agree	32	6.4

 Strongly agree	433	86.6

Malaria is a major health problem requiring vaccine

 Disagree	30	6.0

 Agree	167	33.4

 Strongly agree	303	60.6

Malaria vaccine will save money spent on treatment

 Disagree	23	4.6

 Indifferent	67	13.4

 Agree	129	25.8

 Strongly agree	281	56.2

Malaria vaccine will not have adverse health effect

 Strong degree	61	12.2

 Disagree	109	21.8

 Indifferent	20	4.0

 Agree	101	20.2

 Strongly agree	209	41.8

Malaria vaccine will save man hour lost to malaria

 Agree	199	39.8

 Strongly agree	301	60.2


Function Name	Operations Number/Pixel

“format”	10

“format_bis”	14

“sobel”	15

“prewitt”	14

“matrix”	8

“filter”	10 × 3

“filtre_gauss”	(12 + 6 × (filter size)) × 3

“critere_Harris”	10

“critere_Shi”	31

“look_for_max”	6


Reference	Country	Number ofpatients with BP	Goldstandard	BP180	BP230

Sensitivity	Specificity	Sensitivity	Specificity

Tampoiaet al.20	Italy	36	ELISA	85%	100%	44%	100%

van Beeket al.18	Germany	42	ELISA	100%	98%	55%	100%

Zarianet al.19	Italy	18	ELISA	83%	100%	39%	100%

Chianget al.*17	Australia	18	ELISA	77%	84%	94%	63%


	"IUI + IVF" for those failing IUI

IUI modality	One cycle of IUI	Two cycles of IUI	Three cycles of IUI	Four cycles of IUI	Five cycles of IUI	Six cycles of IUI

U-IUI (LBR = 3.5%)

Cost difference "IUI+IVF" vs. primary IVF	£2,600	£36,100	£70,100	£104,400	£139,100	£174,200

No of IVF cycles that would be purchased by the cost difference	1	11	22	32	43	54

No of live birth-producing pregnancies expected from IVF cycles that would have been purchased by the cost difference	0	4	6	8	11	14

S-IUI (LBR = 7%)

Cost difference "IUI+IVF" vs. primary IVF	£48,100	£122,600	£199,100	£277,200	£356,900	£438,000

No of IVF cycles that would be purchased by the cost difference	15	38	62	86	111	136

No of live birth-producing pregnancies expected from IVF cycles that would have been purchased by the cost difference	4	10	16	22	28	35

C-IUI (LBR = 3%)

Cost difference "IUI+IVF" vs. primary IVF	£34,300	£98,900	£163,400	£228,000	£292,600	£357,200

No of IVF cycles that would be purchased by the cost difference	11	31	51	71	91	111

No of live birth-producing pregnancies expected from IVF cycles that would have been purchased by the cost difference	3	8	13	18	23	28


Variable	Principal Component 1 Loadings	Principal Component 2 Loadings

pH	−0.998

Total dissolved solids	−0.992

Electrical Conductivity	−0.962

Caffeine	0.980

Carbamazepine	0.935

Tonalide		0.997

Galaxolide		0.961

Bisphenol A	0.906

Nonylphenol		0.902

% Variance	51.46	38.53

Cumulative %	51.46	89.99


	Adolescents with type 1 diabetes	U.S. National Norm

	%	n	%	P-value

How would you rate the health of your teeth?*

 Excellent/very good	48.3	43	70.6

 Good	39.3	35	21.5	<.001

 Fair/poor	12.4	11	7.9

How would you rate the health of your gums?			NA

 Excellent	10.2	9

 Very good	33.0	29

 Good	43.2	38

 Fair	12.5	11

 Poor	1.1	1

	%	95% CI	%	P-value

What specific problems, if any, do you have with your teeth and gums?

 Pain/toothache*	5.8	1.9–12.9	10	.19

 Cavities/decayed teeth or cavities*	25.9	16.8–36.9	19.4	.14

 Bleeding gums*	31.8	22.3–42.6	4.0	<.001

 Cosmetic concerns: discoloration**	40.7	30.2–51.8	3.6	<.001

 Orthodontic concerns: crooked teeth**	41.5	30.7–52.9	33.5	.13

 Bad breath	26.7	17.8–37.4	NA

 Plaque or tartar buildup on teeth**	33.3	22.9–45.2	3.6	<.001


		Subset with airborne PAH monitoring and RCPM	Subset with airborne PAH monitoring but missing RCPM

Variable	p-Valueb	Mean ± SD	nc	Mean ± SD	nd

Continuous

 Total valid airborne PAH exposure (ng/m3)	0.65	39.62 ± 48.49	219	39.39 ± 47.70	125

 Dietary exposure to PAHs during pregnancye	0.31	42.49 ± 5.65	219	43.14 ± 6.27	139

 Cord blood cotinine level (ng/mL)	0.49	2.04 ± 11.52	219	3.29 ± 15.56	138

 Cord blood lead level (μg/dL)	0.59	1.60 ± 1.19	210	1.51 ± 0.78	129

 Cord blood mercury level (μg/dL)	0.43	1.07 ± 0.64	161	1.16 ± 0.79	106

 Gestational age (days)	0.07	39.26 ± 1.73	219	39.51 ± 1.63	139

 Birth weight (g)	0.01	3368.49 ± 508.38	219	3501.65 ± 474.22	139

 Birth height (cm)	0.76	54.44 ± 3.06	219	54.54 ± 3.10	139

 Head circumference at birth (cm)	0.21	33.81 ± 1.54	219	34.01 ± 1.47	139

 Maternal age (years)	0.01	28.50 ± 3.59	219	27.49 ± 3.73	139

 Maternal height (cm)	0.18	164.69 ± 5.71	219	165.52 ± 5.59	139

 Maternal prepregnancy weight (kg)	0.95	58.44 ± 8.80	219	58.50 ± 9.32	139

 Maternal TONI-3	0.23	33.48 ± 9.07	176	31.42 ± 9.71	31

 Maternal blood cotinine level at birth (ng/mL)	0.97	1.68 ± 10.09	219	2.99 ± 14.34	138

 Maternal blood lead level at birth (μg/dL)	0.79	1.92 ± 0.83	209	1.86 ± 0.66	136

Categorical	p-Valuef	Proportion	n	Proportion	n

 Caucasian race	1.00	1.00	219	1.00	139

 Maternal education (proportion graduated high school, i.e., 12 years of schooling)	0.47	0.91	219	0.88	139

 ETS in the home (yes = 1, no = 0)	0.52	0.22	219	0.25	139

 Exposure to alcohol during pregnancy (yes = 1, no = 0)	0.18	0.60	219	0.67	139

 Sex of the child (proportion female)	0.52	0.52	219	0.48	139


Descriptor	FTU Dosing Study	Tape-Stripping Study

Age (years)	27.2 ± 10.3	26.0 ± 3.7

Gender	14 male; 10 female	3 female; 2 male

Fingertip length (mm)	28 ± 3	Not applicable

Previous use of TCS	9 yes; 15 no	No recent use

PIL offered?	12 yes; 12 no	Not applicable

If yes; PIL read?	8 yes; 4 no


Author	Year	Country	Limb	Test timing, h

Arlettaz et al.	2006	Switzerland	Right or left foot	6–12

Bakr and Habib	2005	Egypt	Right upper and lower limbs	31.7 (average)

de Wahl Granelli et al.	2005	Sweden	Right hand and one foot	12–48

Hoke et al.	2002	America	Right arm and either leg	24 (average)

Koppel et al.	2003	America	—	>24

Richmond et al.	2002	UK	One or other foot	>2

Rosati et al.	2005	Italy	—	72 h (median)

Zhao et al.	2014	China	Both on the right hand and on either foot	6–72

Riede et al.	2010	Germany	Foot	24–72

Mathur et al.	2015	India	Right upper limb and either foot	72 (median)

Hu et al.	2016	China	Right hand and either foot	25 (median)

Jones et al.	2016	UK	—	<24

Ozalkaya et al.	2016	Turkey	Lower and right upper extremity	>24

Jawin et al.	2015	Malaysia	Left foot	20 (median)

Ewer et al.	2011	UK	Right hand and either foot	In the first few hours

Taksande et al.	2013	India	All the four limbs	Within the first 4 hours

van Niekerk et al.	2016	South Africa	—	60 (median)

de-Wahl Granelli et al.	2009	Sweden	Right hand and either foot	38 (median)

Meberg et al.	2008	Norway	Foot	<12

Mo et al.	2015	China	Right hand and either foot	>24

Jia et al.	2016	China	Right hand	24

Lu et al.	2016	China	Right hand and right foot	>24


ID	HISTOLOGY	Age at diagnosis(years)	Race	Smoking	Drinking	Menopausal status	BMI (Kg/m2)	CYP1B1(V432L) *

5	Intra Ductal Carcinoma	68	White	Never	Unknown	Post	51.16	Wild type

8	Intra Ductal Carcinoma	45	White	Never	No	Pre	38.39	Wild type

9	Intra Ductal and Lobular Carcinoma	51	White	Never	No	Post	26.63	Wild type

1	Intra Ductal Carcinoma	44	White	Never	Yes	Pre	22.49	Heterozygous

2	Intra Ductal Carcinoma	56	White	Never	No	Post	37.12	Heterozygous

6	Intra Ductal Carcinoma	69	White	Never	No	Post	35.51	Heterozygous

3	Intra Ductal Carcinoma	60	White	Never	No	Post	21.45	Homozygous variant

4	Intra Ductal Carcinoma	67	White	Never	Yes	Post	27.36	Homozygous variant

7	Metaplastic carcinoma	46	White	Never	No	post	23.51	Homozygous variant


Type of use	Unit costs

Costs in the health care system (public/private)	General practitioner	10.5/27.5

Nurse or psychiatric nurse	10.0/25.4

Social worker	14.9/25.4

Psychologist	70.6/70.6

Psychiatrist	42.9/42.9

Other medical specialists	51.1/51.1

Hospital emergency visits	155.5

Hospital stay	617.5

Diagnostic tests (range)	4.3 to 434.6

Pharmacologic treatment	Depending on type and dose

Productivity losses	Absenteeism from work (minimum and medium daily wage)	21.4 to 62.7

CBT costs	Cost of the group intervention per session (eight patients/group; nine sessions)	240


 	Case 1	Case 2	Case 3	Case 4	Case totals	Stakeholders	Total

Sharp-end interviews	17	4	0	12	33	98

Blunt-end interviews	7	0	20	10	37

Total	24	4	20	22	70	98	168


Variable

Age	56–65 years: 58(43%)	46–55 years: 37(27.4%)	36–45 years: 24(17.8%)	Under 35 years: 11(8.1%)

Contract with sickness fund	§ 2-Vertrag (regional sickness funds): 86(78.5%)	Small sickness funds (BVA, SVA, KFA, VA, SVB): 90(78. 9%)	“Wahlarztstatus” (private doctora): 22(16%)	“Wohnsitzärzte”b: 11(8.1%)

Locum physician: 16(12%)

Assistance	Receptionist: 120(90.2%)	Practice nurse: 34(25.6%)	Secretary: 48(36.1%)	Other employees:Cleaning worker: 29Masseur: 7Physiotherapist: 4Medical technical assistant: 3

Number of inhabitants in the area of the office	<4999: 68(50.7%)	5000–99,999: 22(16.4%)	10,000–29,999: 12(9%)	>30,000: 32(23.9%)

“Regelfälle”c/quarter	<500 “Regelfälle”: 13(10.2%)	500–1000 “Regelfälle”: 24(18.8%)	1001–1500 “Regelfälle”: 61(47.7%)	>1500 “Regelfälle”: 30(23.4%)

Specialized office	Yes: 69 (51.95%)	No: 64 (48.1%)	–	–

Field of practice specialization	17 GPs:Complementary medicine	8 GPs in each:Manual medicineOrthopedicsSports medicine	7 GPs in each:NutritionGeriatricsPsychosocial/psychosomatic medicine	<6 GPs in each:Preventive medicineHypertensionPain medicineOccupational medicineEmergency medicinePsychotherapyWound management

15 GPs: Diabetes mellitus II management


Differentiation	Subset	Surface phenotype

Progenitor subsets (bone marrow)	Pro-B	B220loCD43+

 	 	AA4.1+

 	Pre-B	B220loCD43−, AA4.1+preBcR+

 	Immature (23−)	B220lo, sIgM+, sIgD−, CD23−

 	Immature (23+)	CD19+, B220+, sIgM+, sIgD−, CD23+

Transitional subsets (spleen)	T1	IgMhiCD23−, B220intAA4.1+

 	T2	IgMhiCD23+, B220+AA4.1+

 	T3	IgMloCD23+, B220+AA4.1+

Mature primary subsets	Follicular zone	IgMloCD23+, B220hiAA4.1−

 	Marginal zone 	CD19+IgMhiIgDlo CD23+ CD21+

 	B1	CD43+ CD23− CD5+

T-independent responses	Early antibody-forming cells/short-lived plasma cells	B220loCD19+slg+iclghi

T-dependent responses	Early antibody-forming cells/short-lived plasma cells	B220loCD19+slg+iclghi

 	Germinal center	B220+CD19+GL7+

 	Long-lived plasma cells	B220loslg−iclg+

 	Memory	B220+slg+IgD−

Natural antibodies	Peritoneal B1a and B1b	CD43+ CD23− CD5+


Reduction Method	Raman (ID/IG)	H (%)	Reference

Mg/HCl	1.52	10.3	[38]

Fe/HCl	1.38	9.8	[35]

Zn/HCl 	1.49	29.6 	[36]

Al/HCl	1.32	7.2 	[38]

NH3BH3/Fe2O3	1.19	43.6	this paper


	Mean ± SD

Age (years)	7.99 ± 1.55

Mother's educational level (years)	4.51 ± 1.43

Weight (kg)	27.63 ± 8.26

Height (cm)	126.28 ± 9.93

BMI‐for‐age (Z‐Score)	0.31 ± 1.31

Height‐for‐age (Z‐Score)	‐1.23 ± 1.22

Percentage body fat	29.12 ± 6.68

Stool leukocytes (CPF)	2.36 ± 1.52

C‐Reactive Protein (mg/L)	0.97 ± 1.60

Interleukin 6 (pg/mL)	3.12 ± 3.95

Interleukin 10 (pg/mL)	4.33 ± 6.82

Tumour necrosis factor‐α (pg/mL)	4.25 ± 2.87


Gene ID	Gene symbol	Fold change	Description

180579	vang-1	0.45	Vang-like protein

3565956	R04A9.7	0.37	Hypothetical protein

174941	cyd-1	0.41	G1/S-specific cyclin-D

179100	fat-7	0.23	Delta(9)-fatty-acid desaturase fat-7

178840	skr-7	0.38	SKp1 related (ubiquitin ligase complex component)

178495	skr-8	0.33	SKp1 related (ubiquitin ligase complex component)

178494	skr-9	0.27	SKp1 related (ubiquitin ligase complex component)

191169	kgb-2	2.03	Mitogen-activated protein kinase

353420	gsto-2	2.14	Probable glutathione transferase omega-2

180148	skr-5	2.31	SKp1 related (ubiquitin ligase complex component)


Number of Cases by Mucormycetes	2010	2011	2012	2013	2014	Total

Apophysomyces elegans	-	1	-	-	-	1

Apophysomyces variabilis	5	2	-	4	1	12

Lichtheimia corymbifera	-	-	1	-	-	1

Lichtheimia ramosa	5	-	-	2	-	7

Mucor irregularis	-	-	-	1	-	1

Rhizopus arrhizus	4	4	5	2	2	17

Rhizopus microsporus	1	1	1	3	3	9

Rhizopus homothallicus	1	-	-	1	-	2

Rhizomucor pusillus	-	1	-	-	-	1

Saksenaea erythrospora	-	-	-	1	4	5

Syncephalastrum racemosum	-	-	-	2	2	4

						60


Scientific literature	Quantitative data from the study communities	Qualitative data from local people in this study

Importance of Dietary Diversity

• DD associated with overall food consumption, energy intake and satiety [51, 64–69]• DD associated with dietary quality, nutrient intake, nutrient density (likely explaining links to child growth and other anthropometric and biochemical markers of nutrition) [68–71]	• DD associated with overall energy intake [46]• DD associated with intake of most nutrients and nutrient adequacy (Mean Adequacy Ratio, MAR) [46]• After controlling for energy intake, DD no longer associated with intake of most nutrients [46]	• DD important for appetite and enjoyment of food• DD important because “each food has its own value”

Drivers of Dietary Diversity

• DD linked to agrobiodiversity in at least seven studies [46, 52, 72–78],• DD associated with forest cover in three studies [47, 52, 79, 80].• DD linked to vegetable production [81]• DD linked to home gardens [52, 82]• Season may increase/decrease DD [83, 84]• Wild food use associated with higher DD [54]• DD also associated with wealth, household size, education and other economic and demographic variables	• DD associated with agrobiodiversity (crop diversity) [46]• DD associated with forest cover [46, 47].• No differences in DD between wet and dry season, but difference in sources of foods [46, 48]• DD associated with wealth and market access but not with sex or education of the head of the household (unpublished data from the study) [46]	• Agriculture, agrobiodiversity• Land use diversity/landscape heterogeneity• Different foods eaten seasonally• Wealth, available cash, land tenure• Livelihood diversity• Family size• Gender• Personality, family tradition, taboos


Scales	Secure	Fearful	Preoccupied	Dismissing

 Cronbach’s alpha 	 0.630 	 0.766 	 0.723 	 0.588


Alcohol/Cannabis Pairs	Mean	SD	Relevant t values

All Alcohol Per Month	M = 42.4	SD = 55.4	t(2573) = 24.0**

Only Alcohol Per Month	M = 20.47	SD = 42.3

All Alcohol Per Month	M = 42.4	SD = 55.4	t(2574) = 16.3**

Simultaneous Drinks Per Month	M = 28.7	SD = 49.4

Only Alcohol Per Month	M = 20.47	SD = 42.3	t(2558) = 8.1**

Simultaneous Drinks Per Month	M = 28.7	SD = 49.4

All Cannabis Per Month	M = 2.8	SD = 1.5	t(2585) = 3.4**

Only Cannabis Per Month	M = 2.6	SD = 1.3

All Cannabis Per Month	M = 2.8	SD = 1.5	t(2572) = 32.4**

Simultaneous Cannabis Per Month	M = 1.9	SD = 1.3

Only Cannabis Per Month	M = 2.6	SD = 1.3	t(2543) = 29.4**

Simultaneous Cannabis Per Month	M = 1.9	SD = 1.3


Score	Histological features of seminiferous tubules	Remark

0	Orderly arrangement of germinal cells with plenty of sperm and spermatids	Normal

I	Preservation of germ cell layers with decrease of sperm and spermatids 	Mild injury

II	Disarray and decrease of germ cell layers with loss of sperm and spermatids 	Moderate injury

III	Absence of germ cell layers 	Severe injury


 	Checklist

1	Are you often thirsty?

2	Do you produce urine frequently?

3	Are you worried about urinary smell?

4	Do you feel numbness of your extremities?

5	Do you have edema in your legs?

6	Do you have cramps in your legs?

7	Are you insensitive to the pain of a small wound or burn?

8	Do you have a feeling of listlessness?

9	Do you feel lightheaded?

10	Is your vision blurry? Is your eyesight getting worse?


	Total protein (mg)	% of solubilization

Process Step	Exp #1	Exp #2	Exp #3	Exp #1	Exp #2	Exp #3

Supernatant 4 M urea wash	1015.2	92.3	246	NE	NE	NE

Pellet 4 M urea wash	1045.2	378	740	NE	NE	NE

Supernatant 8 M urea solubilization	905.8	264	589	86	69.8	79.5

Pellet 8 M urea solubilization	24	16.5	23	NE	NE	NE


First author (ref)	Number of subjects with depression	Number of subjects without depression	Total numbers of subjects	Crude RR (95% CI)	Multivariable Adjusted RR (95% CI) reported in paper	Adjustment factors for multivariable RR

	Cancer	No cancer	Cancer	No Cancer

Kaplan (8)	117	N.a.	612	N.a.	6,848	-	0.97 males 1.27 females	Age, sex

Zonderman (10)	110	892	527	4,874	6,403	1.13 (0.93–1.37)	1.1 (0.9–1.4)	Age, sex, marital status, smoking, family history of cancer, hypertension, cholesterol level

Linkins (11)	25	343	144	1,752	2,264	0.89 (0.59–1.35)	1.09 (0.69–1.71)	Age

Vogt (20)	N.a.	N.a.	N.a.	N.a.	1,529	1.08 (0.79–1.49)	1.08 (0.77–1.52)	Age, sex, social class, Smoking, duration of health plan membership

Knekt (17)	29	295	486	5,298	7,018	1.07 (0.75–1.52)	0.99 (0.68–1.44)	Age, sex

Penninx (19)	16	130	386	4293	4825	1.33 (0.83–2.13)	1.88 (1.13–3.14)	Age, sex, race, disability, hospital admissions, alcohol, smoking

Gallo (15)	8	82	141	1,338	1,569	0.93 (0.47–1.84)	1.3 (0.6–2.8)	Age, sex, smoking, alcohol

van den Heuvel (22)	9	207	67	2,059	2,342	1.32 (0.67–2.61)	n.a.

Schuurman (23)	95	1,246	3,369	63,656	68,366	1.41 (1.16–1.72)	1.08 (0.88–1.33)	Age, sex, socioeconomic status


 	Induction	Repression

 	Range of SLR (significant to max.)	Number of genes [% of total]	Range of SLR (min. to significant)	Number of genes [% of total]

Spermatocytes HS_38°C versus control	0.82 to 2.21	517 [3.53]	−2.84 to −0.82	909 [6.20]

Spermatocytes HS_43°C versus control	0.49 to 2.43	18 [0.12]	−1.35 to −0.36	362 [2.47]

Hepatocytes HS_43°C versus control	0.75 to 6.17	155 [1.07]	−3.62 to −0.75	133 [0.92]


Level	Interviewees (data collection method)	Number of interviews /group discussions

National	Ministry of Health (interview)	3

UNICEF (interview)	1

WHO (interview)	1

Province	Provincial Directorate of Health, Nampula, Mozambique (interview)	2

District	District Community Health Managers (9 participants) (focus group)	1

Health Facilities	Health workers (interview)	8

Observations (2 urban health facilities and 2 rural health facilities, each of which were observed for one week)	4

Community	Mothers (interview)	8

Fathers (interview)	8

Community leaders (interview)	5

Community Health Workers (interview)	2

Women (focus groups of 6–12 participants)	3

Men (focus groups of 10–12 participants)	3


	Significant Biomarkers	Physiological Processes

Asthma	Platelet Count	Thrombogenesis

	Serum Sodium	Serum sodium

	ALT	Tissue injury

	Neutrophil Percent	Acute inflammation

Type 1 Diabetes	Serum Sodium	Serum sodium

	Blood Urea Nitrogen	Kidney function

	Platelet Count	Thrombogenesis

	TSH3	Thyroid function

Type 2 Diabetes	Serum Sodium	Serum sodium

	ALT	Tissue injury

	Platelet Count	Thrombogenesis

Duchenne Muscular Dystrophy	Lactate Dehydrogenase	Tissue injury

	Triglycerides	Lipogenesis

	Platelet Count	Thrombogenesis

	AST	Tissue injury

Cystic Fibrosis	Total IgE	IgE antibody response

	Alkaline Phosphatase	Dephosphorylation

	Platelet Count	Thrombogenesis


Characteristic	Levofloxacin N = 370

Age, years

 Mean (SD)	48.0 (20.26)

 Range, n (%)	18–87

≥ 65–< 75	47 (12.7)

≥ 75	43 (11.6)

Sex, n (%)

 Male	82 (22.2)

 Female	288 (77.8)

Race, n (%)

 White	317 (85.7)

 Black or African American	6 (1.6)

 Asian	30 (8.1)

 Other	17 (4.6)

Region, n (%)

 Eastern Europe	277 (74.9)

 Western Europe	0

 North America	9 (2.4)

 South America	39 (10.5)

 Rest of world	45 (12.2)

Diagnosis, n (%)

 Pyelonephritis	306 (82.7)

 cLUTI	64 (17.3)

Creatinine clearance, mL/min, n (%)

 Normal (≥80)	250 (67.6)

 Mild impairment (≥50–< 80)	92 (24.9)

 Moderate impairment (≥30–< 50)	27 (7.3)

 Severe impairment (<30)	1 (0.3)


Characteristic	Group 1 (n = 26)	Group 2 (n = 7)

Urine culture

 Escherichia coli (%)	15 (%57)	5 (%71)

Quinolone resistance (%)	10 (%66.6)	4 (%80)

ESBL (%)	6 (%40)	3 (%60)

Blood culture

 Escherichia coli (%)	5 (%19)	0

Quinolone resistance (%)	5 (%100)	0

ESBL (%)	4 (%80)	0


Variable	n	%

Gender

 Male	30	53.6

 Female	26	46.4

Age (years)

 <40	30	53.6

 ≥40	26	46.4

Have you breastfed beforea

 Yes	19	73.1b

 No	7	26.9b

Number of infants breastfeda

 0	7	26.9b

 1	4	15.4b

 2	3	11.5b

 ≥3	12	46.2b

Academic qualifications

 B.S.	21	37.5

 M.S.	5	8.9

 M.D.	28	50.0

 Ph.D.	2	3.6

Specialty

 Gynecology/obstetrics	10	17.9

 Pediatrics	5	8.9

 Family medicine	16	28.6

 Lactation consultant nurse	13	23.2

 Pharmacist	12	21.4

Number of years in practice

 5–9	23	41.1

 ≥10	33	58.9

How often do you recommend herbal galactagogues for breastfeeding women?

 Quite often	39	69.6

 Sometimes	17	30.4

How often do you discuss herbal galactagogues that breastfeeding women could be using during your consultations with them?

 Quite often	32	57.1

 Sometimes	24	42.9


Breakpoint type	Number	Mean distance from PQS (kb)	Mean distance from PQS in null data (kb)	Median distance from PQS (kb)	Median distance from PQS in null data (kb)	PQS association (median outside C.I.)

All	173	132.7	301 (Equal)	16.4	180.4 (Equal)	Y

		193.8 (Unequal)	C.I. 11.1–24.3	130.5 (Unequal)	Y

All translocations	99	163.6	300.7 (Equal)	13.5	180.1 (Equal)	Y

		193.4 (Unequal)	C.I. 5.9–53.9	130.4 (Unequal)	Y

Subtelomeric translocations only	65	109.5	300.1 (Equal)	4.8	180.6 (Equal)	Y

		208.8 (Unequal)	C.I. 3.5–8.9	129.7 (Unequal)	Y

All var coding translocations	70	156.6	301.1 (Equal)	14.7	180.6 (Equal)	Y

		181.7 (Unequal)	C.I. 4.1–18.5	125.7 (Unequal)	Y

Indels	74	91.4	300.9 (Equal)	20	179.9 (Equal)	Y

		193.4 (Unequal)	C.I. 11.3–28.4	130.3 (Unequal)	Y

Var-coding events in progeny of 3D7/HB3 cross	24	56.2	300.1 (Equal)	2.9	180.7 (Equal)	Y

		141.1 (Unequal)	C.I. 2.5–11.3	98.8 (Unequal)	Y

Analysis restricted to subtelomeres	119	91.3	133.5 (Equal)	9.1	22.8 (Equal)	Y

		122.1 (Unequal)	C.I. 6.3–15.4	18.8 (Unequal)	Y


 	Cut-points (%) or ($)

Percent of population 25 and over that attended any college (Education)

 1 – Low SES	0 – 39.4

 2	39.5 – 51.5

 3	51.5 – 65.9

 4 – High SES	65.9 – 100.0

Percent of housing units with one or more persons per room (Crowding)

 1 – Low SES	7.6 – 65.6

 2	3.7 – 7.6

 3	1.8 – 3.7

 4 – High SES	0 – 1.8

Average per capita income in 1999 (Income)

 1 – Low SES	3729 – 16 016

 2	16 017 – 20 040

 3	20 041 – 26 224

 4 – High SES	26 225 – 114 359

Percent of population in the civilian workforce that was unemployed in 1999 (Unemployment)

 1 – Low SES	7.5 – 83.9

 2	5.0 – 7.5

 3	3.5 – 5.0

 4 – High SES	0 – 3.4


Source	Sum of squares	d.f.	Mean square	F-value	p-value

Level of training	113.270	2	56.635	13.382*	.000

Score in dimensions of mini-CEX	33.810	5.566	6.075	29.153*	.000

Level of training x Dimensions of mini-CEX	8.161	11.132	0.733	3.518*	.000

Error

Between subjects	3457.727	817	4.232

Residual Error	947.520	4547.337	0.208


Name	Sequence	Description

NIP5;1_qRT-PCR-1	caccgattttccctctcctgat	Probes for realtime PCR

NIP5;1_qRT-PCR-2	ctctttcttactctctagcctc

NIP5;1_qRT-PCR-3	gaatgttcccacgaactcgg

NIP5;1_qRT-PCR-4	acattcatcttgatattcacc

NIP5;1_qRT-PCR-5	gcatgcagcgttaccgatta

PP2A_qRT-PCR-1	ccatgtttgaggatcttacgc

PP2A_qRT-PCR-2	tgtctacatctcagcttcagtgtc

PP2A_qRT-PCR-3	gctccaacaatttcccaaga

PP2A_qRT-PCR-4	caagattcggttagattattg

PP2A_qRT-PCR-5	gcgagaaattgacaatcacag

NIP5;1_mRNA_F	atttaggtgacactatagtaagctcaaagactaaccaaac	For amplification of the standard DNA fragments

NIP5;1_mRNA_R	ttacacatgccatagattttat

PP2A_mRNA_F	atttaggtgacactatagcggtctcatttctcgttcttc

PP2A_mRNA_R	cacttgataagtaaattatttg


sCr (mg/dl)	AKI group	non-AKI group	P value

	(n = 11)	(n = 39)

Preoperative	0.72 ± 0.14	0.68 ± 0.15	0.531

Postoperative

1 day	0.83 ± 0.11	0.69 ± 0.16	<0.05

Postoperative

2 days	1.04 ± 0.15	0.78 ± 0.19	<0.01

Postoperative

3 days	1.05 ± 0.12	0.77 ± 0.18	<0.01


Germplasm or genotypes	Sites (No)	Reference

Type	Number

Natural accession	124	1	Mengesha et al. (1965)

Hybrids	559	1	Berhe et al. (1989a,b,c)

Natural accession	21		Bekele (1996)

Natural accession	225		Ketema (1993)

RIL (key Murri × Fesho)	165	3	Tefera et al. (2003b)

RIL (key Murri ×E. pilosa)	200	3	Tefera et al. (2003a)

F2 (12 crosses)	12	1	Tefera et al. (2008)

Natural accession	320	2	Assefa et al. (1999, 2000)

Natural accession	120	4	Assefa et al. (2001b)

Natural accession	1080	1	Assefa et al. (2001a)

Natural accession	3000	1	Assefa et al. (2002a,b, 2003b)

Natural accession	3600	1	Kefyalew et al. (2000)

Natural accession	144	2	Adnew et al. (2005)

RIL (196 × 974)	196	2	Chanyalew et al. (2006)

RIL (196 × 2356)	190	2	Chanyalew et al. (2009)

RIL (Kay Murri ×E. pilosa)	94	3	Yu et al. (2007)

Natural accession	37	1	Ayalew et al. (2011)

Natural accession	15	1	Plaza-Wüthrich et al. (2013)

Natural accession	81	1	Lule and Mengistu (2014)


Fracture sites	No. of fractures	Fracture IR (/1000 PY)	Age/sex adjusted HR (95 % CI)	Adjusted HR (95 % CI)

Major osteoporotic fracture

 Never-GLP1-ra usea	4373	6.1	Reference	Reference

 Current GLP1-ra use	44	3.7	0.97 (0.71–1.31)	0.97 (0.72–1.32)b

Hip fracture

 Never-GLP1-ra usea	1383	1.9	Reference	Reference

 Current GLP1-ra use	2	0.2	0.26 (0.06–1.03)	0.27 (0.07–1.08)c

Radius/ulna fracture

 Never-GLP1-ra usea	1442	2.0	Reference	Reference

 Current GLP1-ra use	15	1.3	1.78 (0.47–1.32)	0.82 (0.48–1.37)d

Vertebral fracture

 Never-GLP1-ra usea	513	0.7	Reference	Reference

 Current GLP1-ra use	8	0.7	1.59 (0.78–3.24)	1.64 (0.80–3.37)e


 	PR	GR	CS	OD	IT	FL

PR	—	MI	WI	EI	SI	VSI

GR		—		SMI

CS		WI	—

OD			SI	—	WI	SI

IT		SMI	MI		—

FL		WI	EI		MI	—


	TNF-α Stimulation (U/ml)

0	10	100

HUVECs in monocultures	4.9 ± 1.5	15.7 ± 0.8*	24.57 ± 3.01**

HUVECs in direct contact with podocytes	11.43 ± 4.7	21.53 ± 5.7	38.7 ± 9.8*

HUVECs with no direct contact	5.7 ± 1.13	14.5 ± 1.9*	24.01 ± 1.6**


Plasmid	Description	Source of reference

pGK423	Yeast expression vector containing PGK1 promoter, 2 μ origin, HIS3 marker, no expression (control plasmid)	Ishii et al. [10]

pGK426	Yeast expression vector containing PGK1 promoter, 2 μ origin, URA3 marker, no expression (control plasmid)	Ishii et al. [10]

pGK406	Yeast integration vector containing PGK1 promoter, URA3 maker	Ishii et al. [10]

pATP425	Yeast three gene expression vector containing ADH1, TDH3, and PGK1 promoters, 2 μ origin, LEU2 marker, no expression (control plasmid)

pATP424	Yeast three gene expression vector containing ADH1, TDH3 and PGK1 promoters, 2 μ origin, TRP1 marker, no expression (control plasmid)

pATP423	Yeast three gene expression vector containing ADH1, TDH3 and PGK1 promoters, 2 μ origin, HIS3 marker, no expression (control plasmid)

pGK423-kivd	HIS3, expression of L. lactis kivd gene	Kondo et al. [14]

pGK423-ARO10	HIS3, expression of S. cerevisiae ARO10 gene	Kondo et al. [14]

pGK423-THI3	HIS3, expression of S. cerevisiae THI3 gene	Kondo et al. [14]

pGK426-ADH1	URA3, expression of S. cerevisiae ADH1 gene	Kondo et al. [14]

pGK426-ADH2	URA3, expression of S. cerevisiae ADH2 gene	Kondo et al. [14]

pGK426-ADH5	URA3, expression of S. cerevisiae ADH5 gene	Kondo et al. [14]

pGK426-ADH6	URA3, expression of S. cerevisiae ADH6 gene	Kondo et al. [14]

pGK426-ADH7	URA3, expression of S. cerevisiae ADH7 gene	Kondo et al. [14]

pGK426-SFA1	URA3, expression of S. cerevisiae SFA1 gene	Kondo et al. [14]

pGK426-cimA	URA3, expression of M. jannaschii cimA gene	This study

pGK406-cimA	URA3, genomic integration of M. jannaschii cimA gene	This study

pATP425-leuC(Cb)-leuD(Cb)	LEU2, co-expression of C. beijerinckii leuC and leuD genes	This study

pATP425-leuC(Ec)-leuD(Ec)	LEU2, co-expression of E. coli leuC and leuD genes	This study

pATP425-leuC(Mj)-leuD(Mj)	LEU2, co-expression of M. jannaschii leuC and leuD genes	This study

pATP425-cimA-leuC(Cb)-leuD(Cb)	LEU2, co-expression of M. jannaschii cimA, C. beijerinckii leuC and leuD genes	This study

pATP425-cimA-leuC(Ec)-leuD(Ec)	LEU2, co-expression of M. jannaschii cimA, E. coli leuC and leuD genes	This study

pATP425-cimA-leuC(Mj)-leuD(Mj)	LEU2, co-expression of M. jannaschii cimA, leuC and leuD genes	This study

pATP424-ILV1	TRP1, expression of S. cerevisiae ILV1 gene	This study

pATP424-tdcB	TRP1, expression of E. coli tdcB gene	This study

pATP424-ilvA	TRP1, expression of E. coli ilvA gene	This study

pATP424-tdcB-asd	TRP1, co-expression of E. coli tdcB and asd genes	This study

pATP423-thrA-thrB-thrC	HIS3, co-expression of E. coli thrA, thrB and thrC genes	This study


Antibody(ies)	Number of patients	Percentage

Alloantibodies

Anti-c	10	6.4

Anti-C	3	1.9

Anti-c and anti-E	10	6.4

Anti-C + D	8	5.1

Anti-C + D + E	1	0.6

Anti-D	25	16.0

Anti-e	1	0.6

Anti-E	57	36.3

Anti-Fya	1	0.6

Anti-Jka	3	1.9

Anti-K	7	4.5

Anti-Kpa	1	0.6

Anti-Lea	4	2.5

Anti-Lua	1	0.6

Anti-M	4	2.5

Auto- + alloantibodies

Auto- + alloanti-c	2	1.3

Auto- + alloanti-E	3	1.9

Auto- + alloanti-K	3	1.9

Auto- + alloanti-S	1	0.6

Not determined	12	7.6

Total	157	≈100%


Genotype	Strain	Accession number	Genotype	Strain	Accession number

GI_1	NV-USA93	M87661	GII_6	SU3-JPN 	AB039776

GI_2	SOV-GBR93	L07418	GII_7	GN273-USA93	AF414409

GI_3	VA98115-USA98	AY038598	GII_8	SaU25-JPN 	AB039780

GI_4	B493-GER93 	X76716	GII_9	VA97207-USA97	AY038599

GI_5	SzUG1-JPN 	AF414406	GII_10	Erfurt-DEU00	AF427118

GI_6	BS5-GER 	AF093797	GII_11	SW918-JPN97	AB074893

GI_7	Wnchest-GBR94	AJ277609	GII_12	Gifu-JPN96	AB045603

GI_8	Boxer-USA01	AF538679	GII_13	G5175B-AUS83	DQ379714

GII_1	Hawaii-USA94	U07611	GII_14	8533Maizuru-JPN08	GU017903

GII_2	SMV2-USA	AY134748	GII_15	Me7076-USA99 	AF542090

GII_3	SU201-JPN 	AB039782	GII_16	Tiffin-USA99	AY502010

GII_4	Lordsdale-UK	X86557	GII_17	CSE1-USA02	AY502009

GII_5	MOH-HUN99	AF397156


 	0–30 days post-implant	31–60 days post-implant	61–90 days post-implant

Pacemaker	35%	30%	67%

ICD	36%	42%	66%

CRT-D	34%	32%	77%


Species	Number detected	(high; medium; low; no visible mould)

Epicoccum nigrum	15	(7,2,4,2)

Cladosporium cladosporioides	7	(3,3,1,0)

Aureobasidium pullulan	4	(1,1,2,0)

Cryptococcus flavescens	3	(1,2,0,0)

Alternaria alternata	2	(1,1,0,0)

Alternaria tenuissima	1	(0,0,1,0)

Aspergillus westerdijkiae	1	(0,0,1,0)

Candida parapsilosis	1	(0,1,0,0)

Cladosporium silenes	1	(0,0,0,1)

Cladosporium tenuissimum	1	(0,1,0,0)

Cladosporium uredinicola	1	(1,0,0,0)

Cochliobolus lunatus	1	(0,1,0,0)

Curvularia brachyspora	1	(0,1,0,0)

Curvularia trifolii	1	(0,1,0,0)

Leptosphaerulina australis	1	(0,1,0,0)

Paraphaeosphaeria sp	1	(1,0,0,0)

Penicillium fellutanum	1	(0,0,1,0)

Penicillium oxalicum	1	(0,1,0,0)

Penicillium polonicum	1	(0,0,0,1)

Penicillium spinulosum	1	(0,0,1,0)

Phoma herbarum	1	(0,0,1,0)

Rhodotorula slooffiae	1	(0,1,0,0)

Total	48


ROSA item	Symptom domain	Factor	Loading

1	The patient is able to remember events from a long time ago.	Cognition	Factor 1	0.6857

2	The patient is able to remember events of the recent past.	Cognition		0.7448

3	The patient is able to plan and carry out complex procedures.	Cognition		0.8526

4	The patient is able to make himself understood.	Communication		0.7138

5	The patient is able to communicate.	Communication		0.7966

6	The patient shows social competence.	Communication		0.7289

12	The patient is competent at everyday tasks.	Function/ADL		0.7791

13	The patient is attentive, shows interest in his surroundings.	Function/ADL		0.7284

14	The patient is independent.	Function/ADL		0.7849

15	The patient's quality of life is (very good/very poor).	Quality of life		0.4509

16	The burden for the caregiver is (very small/very large).	Caregiver burden		0.6183

7	The patient behaves aggressively.	Behavior	Factor 2	0.7309

8	The patient is restless.	Behavior		0.6248

9	The patient shows behavioral changes due to delusions.	Behavior		0.7397

10	The patient is insecure.	Behavior		0.5014

11	The patient's behavior is cooperative.	Behavior		0.6243


	Hill and Upchurch7	Alkema et al2

Type	Prescriptive	Descriptive

Data	Historical series from four Northwestern European countries (England and Wales, France, the Netherlands and Sweden) and New Zealand, between 1820 and 1964	All available data from vital registration systems, sample registration and surveillance systems, surveys and censuses from 195 countries since 1950.

Age ranges	Infant (<1 year), child (1–4 years) and under 5 (<5 years)

	Intended to reflect sex differentials in childhood mortality in the absence of substantial discrimination, but at relatively high levels of child mortality. Described by the authors as a mortality ‘standard’.	Intended to reflect actual sex ratios in mortality, regardless of the presence of gender bias. Country-specific sex ratios are presented; these results are based on the product of the expected sex ratio and a country-specific multiplier, which represents the relative advantage or disadvantage of girls to boys compared with other countries with similar total mortality rates.

Original estimates

Assessment of gender bias	Female advantage index (difference between the observed and expected female/male mortality ratios) for any given level of male mortality	Countries with outlying sex ratios. Excess female mortality expressed as the difference between the expected and estimated female mortality rates


Chemokine	Forward primer	Reverse primer	Product size (bp)

CCL-chr25s	5'-TTCTGCTGTTTTTGGTGTTCA	5'-GCTTTATCCAGTCCTCATCTGG	216

CCL-chr24a	5'-TACTTCTCAGCTTCCTTGTGGAGA	5'-CTCATCGTCTTCGTCTTCATTGTT	250

CXL-chr24a	5'-AGGTTGGAGCAGTACCGACAA	5'-CCTCCCCTCTACACGTTACCC	245

CCL-chr24c	5'-ATGCGTCTGTCCTCAGCTTT	5'-GCTGTCGGATCTATGCAGTG	284

CCL-chr24m	5'-AGGAGTTTGGCTGTTGCACT	5'-CCTCCTCACCCACAGTTGTC	219

CCL-chr20d	5'-CAGACAAGTGCTGCTTTTCG	5'-GAGCTGGCCTCTGTGTCTTT	209

CCL-chr20g	5'-CGCTTTCTGCTCAGTTGTTG	5'-TCAGTCTCCGAACCCATTTC	215

scybaa	5'-TGCAGATGCACAAGAAAAGG	5'-GGCTTCAAACGTCCTGTGTT	225

cxcl12aa	5'-TTCATGCACCGATTTCCAAC	5'-TGTTGATGGCGTTCTTCAGG	222

CXCL-chr13a	5'-CAACATGTCCCAAAGACCTG	5'-TTACCTGTTCCAACATTTCATTAGA	201

CXCL-chr13c	5'-ACTGCCCATCCAGCAGTTAC	5'-TCCTGCCTTCGATGATCTTT	200

CXCL-chr13d	5'-TTGTTTTTGGAGTCAGCATCA	5'-AGTGTGTTCTGGGGTTCAGG	222

CCL-chr11a	5'-CCAGCATCGCACAAGGTTAC	5'-GCCTGGACCCAGTCACTTCT	208

CCL-chr11b	5'-ATGCAGCGAGATGTTCAGTG	5'-GGAATTCACAACAGCGACCT	282

CCL-chr10a	5'-CGATGATGCAGTGGATTGTT	5'-TTTCCTGGGTCGTTTTTGTG	235

CCL-chr10b	5'-TACTGTGCATCGCCTTCAGC	5'-TAGACGAGCCATTCGCTTCA	233

ccl1a	5'-GGCACGAGATGGAGTTCAGA	5'-GCCGTCTGTATCCGTGATTT	329

CCL-chr5a	5'-ACGGTCAGCCCAAGAGTCAT	5'-GAGCATGACAGCGTCTCTCG	229

CCL-chr5b	5-CCATAACTCTCCTGCTCATCG	5'-GCGCAGAGTTTCTTGTCCTT	202

CXCL-chr5c	5'-AAGTGCGTGCCTGATAAACC	5'-CACATCAACTGCCTGAATGG	229

CXCL-chr5d	5'-TGTTACTGCTCTGCTTCTTGTCA	5'-CATCGTTTTCCAGCTCCATT	204

CXCL-chr1c	5'-TACGTCCAGCAGGGAGAAGT	5'-CCCTGCTGTTTTTGTGGATT	218

CCL-chrUi	5'-GACTTCTGGCCGTCACATTC	5'-AGCTGAGGGTCCACACAGAG	202

β-actin	5'-TGTTCGAGACCTTCAACACC	5'-TGAAGGTGGTCTCGTGGATA	471


Gender	Male

Age	10 y

Diagnosis	Oppositional defiant disorder

Intellligence quotient (IQ)	59

NCBRF total score

 Baseline	33

 Endpoint	31

Time point	Risperidone dose (mg/day)	Dyskinesia score*

 Baseline	0.000	3

 Week 1	0.343	3

 Week 2	1.200	3

 Week 3	1.814	3

 Week 4	1.900	3

 Week 8	1.784	---

 Week 12	1.300	4

 Week 16	1.300	7

 Week 20	1.300	7

 Week 24	1.300	1

 Week 36	1.300	2

 Week 48	1.300	0


	Screening	Pretreatment	Discharge	End of Intervention	Follow-up

Study visits		T0	T1	T2	T3

Written informed consent	X

Screening questions	X

BDI-II	X		X	X	X

GAD-7		X	X		X

PHQ-9		X	X		X

RSE		X	X		X

EUROHIS-QOL 8		X	X		X

DAS		X	X		X

CTQ		X

WAI		X	X		X

OPD-SQ		X

HAQ			X

Satisfaction with intervention			X	X

Utilization of other treatment					X

BADO		X	X

Willingness to pay				X

Adverse events		continuously	X	X


Goal	I have set this goal (N)	Since joining K-DPP, I have made lifestyle changes to achieve this goal (%)	I will continue to make these changes after the intervention

Very likely (%)	Likely (%)	Not sure (%)

Improving diet	346	99	83	15	2

Increasing physical activity	306	96	67	32	1

Reducing smoking/tobacco	51	76	82	18	–

Reducing alcohol consumption	62	98	56	34	10


Isoform	Substrate	Metabolite	Ranges of substrate concentrations in the incubations, μM	Fluorescence detection excitation/emission

CYP1A	ER	resorufin	0.1–12.0	560/586 nm

CYP2A	coumarin	hydroxycoumarin	2.5–300.0	338/458 nm

CYP3A	BFC	HFC	0.4–120.0	410/538 nm


SNPs	No. of every SNP type	Caused by	Total No. of transition and transversion

A/G	28769	Transition	53208

C/T	24439

A/C	6832	Transversion	30667

G/T	12016

A/T	4315

G/C	7504


Term	Definition

SP-trEMBL	Sequence dataset containing 2,241,227 sequences from the Swiss-Prot (version 48.1) and TrEBML (version 31.1) sequence databases.

Integr8_263	Sequence dataset containing 913,094 sequences from 263 completed genomes listed in the Integr8 genome database.

Pfam_struc	Pfam-A family containing a PDB structure that has not yet been classified into the CATH domain database.

NewFam	Protein families generated in the Gene3D


	EDA group (n = 68)	Opioid group (n = 98)	p-value

Age (years)	59.3 ± 16.0	59.9 ± 15.3	n.s.

Male gender (%)	58.8	66.3	n.s.

Hospital stay (days)	9.8 ± 5.7	11.1 ± 9.4	n.s.

Pre-existing pain therapy (%)	8.8	9.2	n.s.

Dismission with oral opioid (%)	73.5	76.5	n.s.

Opiod dose after dismission (mg)	27.7 ± 15.2	28.3 ± 16.4	n.s.

Time to first dejection (days)	3.5 ± 1.8	3.9 ± 2.2	n.s.

EDA duration (days)	4.5 ± 2.0	-


Reference	Numbers studied	Type of controls	Susceptibility	Severity	Ethnicity

	Cancer	Controls

Hefler LA et al, 2005 [58]	269	227	Women visiting outpatient dept for various reasons	No association	No association	Caucasian

Our study	691	420	Women with normal mammograms from screening population	No association	No association	British Caucasian


Simulation Results	Yeast 5	Yeast 6

Auxotroph-inducing genes	92	93

Correct auxotrophy predictions	57	64

Mutant incorrectly predicted to be viable in minimal medium	32	26

Mutant incorrectly predicted to be inviable in supplemented medium	3	3


Subgroups	n	Cases of the grade of tracheal intubation conditions (1/2/3/4)	Cases of the anaphylaxis score (0/1/2/3)	Duration of surgery (min)

Group 1	39	29/10/0/0	32/7/0/0	69 ± 34

Group 2	37	29/8/0/0	35/2/0/0	75 ± 40

Group 3	39	37/2/0/0	35/2/2/0	76 ± 40

Group 4	40	31/9/0/0	38/2/0/0	67 ± 33


Demographic Characteristics	TOTAL	%

Female	15	75%

Race

 White	15	75%

 Black	4	20%

 Asian	1	5%

Age

 ≤ 30	4	20%

 31–40	0	0%

 41–50	8	40%

 51–60	5	25%

 61–70	2	10%

 ≥ 71	1	5%

Education

 Some or graduate of high school	10	50%

 Some college	5	25%

 College graduate	1	5%

 Post graduate education	4	20%

Have access to e-mail & Internet	19	95%

Location of frequent access to e-mail & Internet

 Home	9	45%

 Library	4	20%

 Multiple sites	5	25%


MiR	Parametric p-value	FDR	Permutation p-value	Geom mean of intensities in class 1	Geom mean of intensities in class 2	Geom mean of intensities in class 3	Geom mean of intensities in class 4

hsa-miR-204-4373094	0.00004	0.02784	< 1e-07	15.74986	11.70222	14.82001	6.94659

hsa-miR-30aSTAR-4373062	0.00035	0.11658	0.00010	7.67985	6.27768	7.25131	6.95430


	Count	%

He/she used to work but is currently unemployed	0	0.00

He/she never worked and neither does now	0	0.00

Clerk (civil or private)	338	63.41

Free professional (tradesman, craftsman)	62	11.63

Doctor, lawyer, engineer, priest, teacher, etc.	75	14.07

Student (college or university)	12	2.25

Blue collar worker (construction worker, farmer)	26	4.88

Housewife	20	3.75

Total	533	100.00


 	Hazard ratio	95% confidence interval	p value

Mean age∗	1.026	1.013–1.040	<0.001

Country of birth, Nordic country	1.446	0.980–2.135	0.063

Chronic physical disease	1.025	0.789–1.332	0.851

Work for the last 3 yrs	0.781	0.588–1.038	0.088

Lifetime history of substance abuse (>1 yr)

Binge drinking	1.001	0.768–1.304	0.995

Heroin∗	1.737	1.261–2.393	0.001

Other opioids	0.938	0.655–1.345	0.729

Sedatives∗	1.404	1.026-1.923	0.034

Amphetamine∗	0.684	0.491–0.953	0.025

Cannabis	1.067	0.791–1.439	0.670

Injection drug use∗	1.430	1.013–2.018	0.042

Mean number of substances used, last 30 days	1.040	0.922–1.172	0.524

Lifetime history of psychiatric problems

Hospitalization	1.099	0.784–1.541	0.583

Suicide attempt	1.136	0.839–1.539	0.410


Factor	Score

Vascular invasion

 no	0

 yes	2.6

BCLC stage

 0-A	0

 B-C	1.3

MiR-145

 negative	0

 positive	1.3

MiR-31

 negative	0

 positive	1.7

MiR-92a

 negative	0

 positive	1


Time for data collection	Participants in the interviews

May–September 2013	Unit managers, n = 20Regional coordinators, n = 4Officials, n = 24

May–September 2014	Unit managers, n = 5Officials, n = 16